US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Year-end report January - December 2019

Investments in growth brings Biotage’s annual sales past the billion SEK milestoneFourth quarter October - December 2019 ·Net sales amounted to 288.6 MSEK (234.6), an increase by 23.0 percent compared to the corresponding quarter last year. At comparable exchange rates and adjusted for acquisitions[1)] sales increased by 8.7 percent. ·Operating profit increased by 5.9 percent to 37.9 MSEK (35.7). ·Result after tax amounted to 18.5 MSEK (27.3). ·Earnings per share amounted to 0.28 SEK (0.42) before and after dilution. ·The cash flow from operating

Year-end report  January - December 2018

Continued strong growth and increased operating profit Fourth quarter October – December 2018 · Net sales amounted to 234.6 MSEK (188.9), an increase by 24.2 percent compared to the corresponding quarter last year. At comparable exchange rates1) and adjusted for acquisitions sales increased by 7.9 percent. · Operating profit increased by 11 percent to 35.7 MSEK (32.3). · Result after tax amounted to 27.3 MSEK (34.6). The decrease is explained by the fact that reported tax increases by 10.5 MSEK to -8.1 MSEK (2.4). Reported tax includes changes in book value of deferred tax

Year-end report for 2015

Fourth quarter, October – December 2015                                                       · Group net sales in the fourth quarter 2015 amounted to 168.5 MSEK (137.8), an increase by 22.4 percent compared to the corresponding period last year. At comparable exchange rates sales increased by 6.4 percent. · Operating profit (EBIT) amounted to 20.2 MSEK (27.2). The comparative period 2014 includes 13.5 MSEK relating to a retroactive reversal of goodwill write-down. Adjusted for this one-time effect the operating profit increased by 6.4 MSEK from 13.7 MSEK last year, an increase by

Year-end report for 2014

Fourth quarter October - December 2014                                                         · Group net sales in the fourth quarter 2014 amounted to 137.8 MSEK (121.6), an increase by 13.3 percent compared to the corresponding period last year. At comparable exchange rates sales increased by 3.2 percent. · Operating profit amounted to 13.7 MSEK (13.4). Compared to the corresponding quarter last year operating profit was charged with 3.9 MSEK higher costs for R&D and 3.7 MSEK higher sales costs relating to variable remunerations and strategic initiatives in the USA. · The

Year-end report for 2013

Fourth quarter October-December 2013                                                                                                     · Group net sales in the fourth quarter 2013 amounted to 121.6 MSEK (113.9), an increase by 7 percent compared to the corresponding period last year. At comparable exchange rates sales increased by 11 percent. · Operating profit for the quarter amounted to 13.4 MSEK (13.5). · The result after tax amounted to 18.5 MSEK (13.6). · Earnings per share amounted to 0.28 SEK (0.19). · The cash flow from operating activities amounted to 21.1 MSEK (

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB (publ)

The shareholders in Biotage AB are hereby summoned to the annual general meeting (the “Meeting”), to be held on Thursday, April 26, 2012, at 4.00 p.m., at the head office of Biotage AB, Vimpelgatan 5 in Uppsala, Sweden. Notice etc.Shareholders who wish to participate in the Meeting musta)    be recorded as a shareholder in the share register maintained by Euroclear Sweden AB on      Friday, April 20, 2012, andb)    notify the company of their intention to participate in the Meeting, no later than Friday, April 20, 2012Notice of participation in the Meeting may be made to the

Year-end report  January - December 2011

Fourth quarter 2011 · Net sales are unchanged and are reported at 116.0 MSEK (116.1). At comparable exchange rates sales increased by 3 percent · The operating result amounted to 9.8 MSEK (-435.9)1) · A 7.3 MSEK (15.0) additional purchase payment for the Biosystems business area divested in 2008 was received from Qiagen · The result after tax amounted to 17.2 MSEK (-424.8)1) · Earnings per share amounted to 0.22 SEK (-5.33)1) · Net cash at December 31, 2001 amounted to 198.4 MSEK (172.7) · During the quarter 648,456 own shares were purchased. At the balance sheet date

Year-end report January - December 2010

Fourth quarter 2010                                                                                    · Net sales increased by 17 percent to 116.1 MSEK (99.5). At comparable exchange rates sales increased by 23 percent and at comparable exchange rates excluding business acquired during the year net sales remained at the same level as last year. · The operating result excluding amortization of goodwill amounted to 8.6 MSEK (3.6). · A 15.0 MSEK (23.4) additional purchase payment was received from Qiagen for the Biosystems business area divested in 2008. · Goodwill has been

There are no items matching the current filter
There are no more items matching the current filter
Back to top